HT Study

Type:
Incidence / prospective cohort
Study Status:
Completed
Enrollment Status:
Closed
Countries:
Rwanda;Zambia
Partners:
Projet San Francisco (PSF-Kigali), Kigali, Rwanda; Zambia-Emory HIV Research Project (ZEHRP)-Lusaka, Zambia; Zambia-Emory HIV Research Project (ZEHRP)-Copperbelt, Zambia; Zambia-Emory HIV Research Project (ZEHRP)-Ndola, Zambia.

 
Study Summary:
 
To estimate the annual incidence of HIV infection, characterize early HIV infection, and prepare clinical trial sites for HIV preventive vaccine efficacy trials for which volunteers from this study cohort may be recruited. Since 1986 in Kigali,  1994 in Lusaka, and 2004 in Ndola, consenting HIV discordant couples have been followed quarterly and provided specialized counseling that includes risk reduction and condom advocacy. IAVI support began in 2004 and completed in 2012.

Protocol B

Type:
Incidence / prospective cohort
Study Status:
Ongoing
Enrollment Status:
Open
Countries:
Kenya;Uganda;South Africa
Partners:
Uganda Virus Research Institute-International AIDS Vaccine Initiative (UVRI-IAVI)-Entebbe, Uganda; Kenya AIDS Vaccine Initiative-Kangemi (KAVI-Kangemi), Nairobi, Kenya; Kenya Medical Research Institute-Centre for Geographic Medicine Research-Coast (KEMRI-CGMRC), Kilifi, Kenya; Medical Research Council (MRC-Entebbe)-Entebbe, Uganda; Medical Research Council (MRC-Masaka)-Masaka, Uganda; Desmond Tutu HIV Foundation (DTHF)-Masiphumele, Cape Town, South Africa; Aurum Institute, Rustenburg, South Africa.

Study Summary:
To estimate the annual incidence of HIV infection, characterize early HIV infection, and prepare clinical trial sites for HIV preventive vaccine efficacy trials for which volunteers from this study cohort may be recruited

LTFU

Study Status:
Ongoing
Enrollment Status:
Open
Countries:
Kenya;Uganda;Zambia;Rwanda;South Africa
Partners:
Kenya AIDS Vaccine Initiative-Kenyatta National Hospital (KAVI-KNH), Nairobi, Kenya; Uganda Virus Research Institute-International AIDS Vaccine Initiative (UVRI-IAVI), Entebbe, Uganda; Zambia-Emory Research Project (ZEHRP)-Lusaka, Zambia; Projet San Francisco (PSF-Kigali)-Kigali, Rwanda; Desmond Tutu HIV Foundation (DTHF)-Masiphumele, Cape Town, South Africa; Medunsa, SA.

Study Summary:
To conduct long-term follow-up and assess the long-term health
status of volunteers who have been enrolled previously in an IAVI-sponsored trial of an investigational HIV vaccine candidate.
To evaluate the frequency of HIV infection in volunteers who
participated in HIV vaccine clinical trials.

To evaluate the persistence of vaccine-induced antibodies in
volunteers who tested HIV positive at the end of the IAVI-sponsored vaccine trial.

To characterize immunological, virological, and immunogenetic
responses in volunteers participating in IAVI-sponsored clinical trials.

Protocol H

Type:
Natural history / prespective cohort
Study Status:
Ongoing
Enrollment Status:
Open
Countries:
Rwanda;Kenya;Zambia;Uganda
Partners:
Projet San Francisco (PSF-Kigali)-Kigali, Rwanda; Kenya AIDS Vaccine Initiative-Kangemi (KAVI-Kangemi), Nairobi, Kenya; Zambia-Emory Research Project (ZEHRP)-Copperbelt-Kitwe, Zambia; Medical Research Council-Entebbe, Uganda (MRC-Entebbe).

Study Summary:
Follow-up of HIV-infected participants

PROTOCOL G

Type:
Prevalence / cross-sectional
Study Status:
Ongoing
Enrollment Status:
Varies across multiple sites
Countries:
Uganda;Zambia;Rwanda;South Africa;Kenya;India;Thailand;Nigeria;Australia;United Kingdom;USA;Ivory Coast
Partners:
Uganda Virus Research Institute-International AIDS Vaccine Initiative (UVRI-IAVI)-Entebbe, Uganda; Zambia-Emory Research Project (ZEHRP)-Lusaka, Zambia; Projet San Francisco (PSF-Kigali)-Kigali, Rwanda; Kenya AIDS Vaccine Initiative-Kenyatta National Hospital (KAVI-KNH), Nairobi, Kenya; YRG Care, Chennai, India; Vaccine Trial Centre, Mahidol University, Bangkok, Thailand; Centre de Diagnostic et de Recherche sur le SIDA et les infections opportunistes (CeDReS), CHU Treichville, BP V3, Abidjan, Côte d’Ivoire; Institute of Human Virology (IHV), Nigeria; National Serology Reference Laboratory (NRL), Australia; St. Stephen’s Centre, London, UK; SUNY Downstate Medical Center, Brooklyn, NY; AFRIMS (Armed Forces Research Institute of Medical Sciences), Bangkok, Thailand.

Study Summary:
To generate broadly neutralizing monoclonal antibodies (mAbs) from volunteers who are HIV infected and have broadly cross-reactive serum neutralizing activity.